Clinical research shows SALCITAL may benefit in the management of pre-diabetes and mild to moderate hyperlipidemia

03 September 2013 | News | By Bureau Report

Bangalore: Clinical research shows standardized extract of Salacia reticulate (SALCITAL, Branded Ingredient of Olive Lifesciences) was safe and may be beneficial in the management of pre-diabetes and mild to moderate hyperlipidemia, according to a study published in the Journal of Medicinal Food (June 2013, 16(6): 564-568)


The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of Salacialeaves and root bark extracts in 29 subjects with pre-diabetes and mild to moderate hyperlipidemia. Subjects received either Salacia extracts or placebo along with therapeutic lifestyle changes for a period of 6 weeks. A statistical significant reduction was observed in low-density lipoprotein cholesterol and fasting blood sugar (FBS) levels at week 3 and 6 when treated with root bark extract. The leaves extract-treated group showed statistically significant reduction in FBS levels at week 6 only, said Dr Shivaprasad, lead author of the study.


“We are very excited by this new publication, which strengthened the scientific standards of the company. Apart from its nutraceutical application, SALCITAL is compatible for applications such as dry drink mixes, ready-to-drink products, nutritional bars and other beverages”, said Anzar, Managing Director of Olive Lifesciences.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

© Copyright 2020. Nuffoods Spectrum. All Rights Reserved.
Website Design & Developed By : SCI Knowledge Interlinks